References
- Rathcke CN, Vestergaard H. YKL-40-an emerging biomarker in cardiovascular disease and diabetes. Cardiovasc Diabetol. 2009;8(1):61. doi:10.1186/1475-2840-8-61.
- Kastrup J. Can YKL-40 be a new inflammatory biomarker in cardiovascular disease? Immunobiology. 2012;217(5):483–91. doi:10.1016/j.imbio.2011.04.007.
- Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull. 2006;53(2):172–209.
- Türkyılmaz K, Öner V, Kırbas A, Sevim MS, Sekeryapan B, Özgür G, Durmus M. Serum YKL-40 levels as a novel marker of inflammation and endothelial dysfunction in patients with pseudoexfoliation syndrome. Eye. 2013;27(7):854. doi:10.1038/eye.2013.92.
- Cetin M, Kocaman S, Canga A, Kırbaş A, Yılmaz A, Erdoğan T, Akgül O, Uğurlu Y, Durakoğlugil ME. Elevated serum YKL-40 level predicts myocardial reperfusion and in-hospital MACE in patients with STEMI. Herz. 2013;38(2):202–09. doi:10.1007/s00059-012-3671-4.
- Pala S, Sari M, Kahveci G, Alizade E, Arslantas U, Uslu A. Plasma YKL-40 elevation on admission and follow-up is associated with diastolic dysfunction and mortality in patients with acute myocardial infarction. Cardiol Res Pract. 2018;2018. https://www.hindawi.com/journals/crp/2018/8701851/
- Yang L, Dong H, Lu H, Liao Y, Zhang H, Xu L, Tan Y, Cao S, Tan J, Fu S. Serum YKL-40 predicts long-term outcome in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Medicine. 2019;98(12):e14920. doi:10.1097/MD.0000000000014920.
- Li K, Chen Z, Qin Y, Wei Y-X. Plasm YKL-40 Levels Are Associated with Hypertension in Patients with Obstructive Sleep Apnea. BioMed Research International. 2019;2019. https://www.hindawi.com/journals/bmri/2019/5193597/
- Ma W-H, Wang X-L, Du Y-M, Wang Y-B, Zhang Y, Wei D-E, Guo -L-L, Bu P-L. Association between human cartilage glycoprotein 39 (YKL-40) and arterial stiffness in essential hypertension. BMC Cardiovasc Disord. 2012;12(1):35. doi:10.1186/1471-2261-12-35.
- Harrison DG, Guzik TJ, Lob HE, Madhur MS, Marvar PJ, Thabet SR, Vinh A, Weyand CM. Inflammation, immunity, and hypertension. Hypertension. 2011;57(2):132–40. doi:10.1161/HYPERTENSIONAHA.110.163576.
- Nadruz W. Myocardial remodeling in hypertension. J Hum Hypertens. 2015;29(1):1. doi:10.1038/jhh.2014.36.
- Cokkinos DV, Belogianneas C. Left ventricular remodelling: a problem in search of solutions. European Cardiology Review. 2016;11(1):29. doi:10.15420/ecr/2016:28:2.
- Katholi RE, Couri DM. Left ventricular hypertrophy: major risk factor in patients with hypertension: update and practical clinical applications. Int J Hypertens. 2011;2011. https://www.hindawi.com/journals/ijhy/2011/495349/
- Iso H, Cui R, Date C, Kikuchi S, Tamakoshi A, Group JS. C-reactive protein levels and risk of mortality from cardiovascular disease in Japanese: the JACC Study. Atherosclerosis. 2009; 207(1):291–97. doi:10.1016/j.atherosclerosis.2009.04.020.
- Woodward M, Rumley A, Welsh P, MacMahon S, Lowe G. A comparison of the associations between seven hemostatic or inflammatory variables and coronary heart disease. J Thromb Haemost. 2007;5(9):1795–800. doi:10.1111/j.1538-7836.2007.02677.x.
- Welsh P, Grassia G, Botha S, Sattar N, Maffia P. Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect? Br J Pharmacol. 2017;174(22):3898–913. doi:10.1111/bph.13818.
- Jin Y, Cao J-N, Wang C-X, Feng Q-T, Ye X-H, Xu X, Yang C-J. High serum YKL-40 level positively correlates with coronary artery disease. Biomark Med. 2017;11(2):133–39. doi:10.2217/bmm-2016-0240.
- Kastrup J, Johansen JS, Winkel P, Hansen JF, Hildebrandt P, Jensen GB, Jespersen CM, Kjøller E, Kolmos HJ, Lind I, et al. High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. Eur Heart J. 2009;30(9):1066–72. doi:10.1093/eurheartj/ehp049.
- Kjaergaard AD, Bojesen SE, Johansen JS, Nordestgaard BG. Elevated plasma YKL‐40 levels and ischemic stroke in the general population. Ann Neurol. 2010;68(5):672–80. doi:10.1002/ana.22220.